Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04718675
Other study ID # KB-0742-1001
Secondary ID 2023-503739-16-0
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 8, 2021
Est. completion date December 2025

Study information

Verified date January 2024
Source Kronos Bio
Contact Director of Clinical Operations
Phone 650-781-5200
Email clinicaltrials@kronosbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL). Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts.


Recruitment information / eligibility

Status Recruiting
Enrollment 280
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Males or females = 18 years old (Parts 1 and 2A); males or females = 12 years old and with a body weight = 40 kg are eligible to enroll with tumor types including soft-tissue sarcomas, Ewing's sarcoma, alveolar rhabdomyosarcoma, NUT midline carcinoma (NMC), or chordoma (Part 2B) - Willing and able to provide consent (and assent for participants between the ages of 12 to <18) - Part 1: Participants who meet at least 1 of the following criteria: 1. Any R/R solid tumor with, in the opinion of the investigator at the time of screening has at least 1 readily accessible biopsy site(s) and who consents to 1 baseline and 1 on-treatment biopsy. If the feasibility of obtaining biopsies changes after the participant has been consented due to changes in clinical or surgical considerations and the participant otherwise meets all eligibility criteria, they may still enroll/or continue on study. 2. Tumor type of interest (see list below) with measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) 1.1 or Positron Emission Tomography (PET) Response Criteria in Solid Tumors (PERCIST) 1.0 for solid tumors or by Lugano Classification or Modified Weighted Assessment Tool (mSWAT) for NHL AND at least 1 measurable scan per one of the above criteria prior to the most recent scan to document the rate of tumor growth before the initiation of study treatment. Tumor types of interest (R/R without other available therapeutic options) are: 1. SCLC 2. Epithelial ovarian cancer, TNBC, or NSCLC 3. Other epithelial solid tumor with evidence of MYC copy number gain based on local testing 4. Diffuse large B-cell lymphoma with documented MYC translocation or Burkitt's lymphoma (as determined by local testing) 5. Sarcoma of histologic subtypes known to be associated with transcription factor fusion, specifically: i. Myxoid/round cell sarcoma ii. Clear cell sarcoma iii. Desmoplastic small round cell tumor iv. Low grade fibromyxoid sarcoma v. Extraskeletal myxoid chondrosarcoma vi. Ewing sarcoma vii. Alveolar rhabdomyosarcoma 6. Chordoma, NUT midline carcinoma, or adenoid cystic carcinoma - Part 2, Cohort A: Participants with histologically or cytologically confirmed solid tumors who have failed, are intolerant to, or are considered ineligible for standard-of-care anti-cancer treatments. Note: Part 2, Cohort A, will include participants with relapsed or refractory solid tumors including NSCLC, TNBC and ovarian cancer. - Part 2, Cohort B: Participants with histologically or cytologically confirmed tumor type of interest without access to or intolerant of other approved therapies, including SCLC. - For both Parts 1 and 2: - Access to a tumor sample for central laboratory testing - Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 - Evaluable or measurable disease, per RECIST 1.1 or PERCIST 1.0 for solid tumors or the Lugano Classification or mSWAT for NHL - Adequate bone marrow and organ function - Recovery from treatment-related toxicities from prior therapies to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade = 1 or to baseline level - Must agree to use highly effective birth control during the trial and for at least 3 months after the last dose of study drug; female participants cannot be pregnant or breastfeeding Exclusion Criteria: - Any other anti-cancer therapies including chemotherapy, immunotherapy, or hormonal therapy within 4 weeks or 5 half-lives (whichever is shorter) - History of surgery (except for diagnostic purposes) or non-palliative radiotherapy within 4 weeks - History of allogeneic transplantation within 6 months - Active central nervous system (CNS) involvement by the underlying malignancy; previously treated CNS metastatic disease is permitted with magnetic resonance imaging (MRI) documentation of stable disease for at least 3 months prior to study start. Participants with SCLC with prior treatment with stereotactic radiosurgery or whole brain radiation therapy for CNS metastatic disease 2 weeks or more before study start may be considered eligible for enrollment if assessed stable and meet all other eligibility criteria. - History of stroke or intracranial hemorrhage within =6 months - History of seizure or seizure disorder, ie, recurrent seizures with an underlying etiology and requiring ongoing anti-epileptic medication - Current use of medications associated with seizure risk - Active infections requiring systemic antibiotic, antiviral or antifungal therapy - Known active coronavirus disease 2019 (COVID-19) - Clinically significant heart disease - Uncontrolled hypertension - Prolongation of QT interval at baseline - Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection - Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease

Study Design


Intervention

Drug:
KB-0742
Oral capsules

Locations

Country Name City State
Spain Hospital Clinic de Barcelona Barcelona
Spain Hospital Clínico San Carlos Madrid
Spain Hospital Universitario Quirónsalud Madrid Madrid
United Kingdom Sarah Cannon Research Institute London London
United States University of Michigan Rogel Cancer Center Ann Arbor Michigan
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Cleveland Clinic - Taussig Cancer Center Cleveland Ohio
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States City of Hope Duarte California
United States Virginia Cancer Specialists Fairfax Virginia
United States MemorialCare - Orange Coast Medical Center Fountain Valley California
United States Pennsylvania Cancer Specialists Research Institute - Gettysburg Cancer Center Gettysburg Pennsylvania
United States Oncology Consultants Texas Medical Center Houston Texas
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Community Health Network Community Cancer Center North Indianapolis Indiana
United States Community Health Network Community Cancer Center South Indianapolis Indiana
United States City of Hope - Orange County Lennar Foundation Cancer Center Irvine California
United States Cedars Sinai Los Angeles California
United States Norris Comprehensive Cancer Center Los Angeles California
United States Precision NextGen Oncology Los Angeles California
United States University of California, Los Angeles (UCLA) Los Angeles California
United States SCRI Tennessee Oncology Nashville Tennessee
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Washington University Saint Louis Missouri
United States South Texas Accelerated Research Therapeutics San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Kronos Bio

Countries where clinical trial is conducted

United States,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1 and Part 2: Incidence of Adverse Events (AEs) Type, incidence, severity, causality and outcome of adverse events (AEs), including serious AEs and AEs at Grade 3 or above, based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 38 months)
Primary Part 1 and Part 2: Number of Participants with Dose Limiting Toxicity (DLT) of KB-0742 Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days
Primary Part 1: Maximally Tolerated Dose (MTD) of KB-0742 Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days
Primary Part 1: Recommended Phase 2 Dose (RP2D) of KB-0742 Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days
Secondary Part 1: Maximal Plasma Concentration (Cmax) of KB-0742 Cycle 1 Day 1 through Cycle 6 Day 1, where a cycle is up to 28 days
Secondary Part 2: Maximal Plasma Concentration (Cmax) of KB-0742 Cycle 1 Day 1 and Cycle 1 Day 12, where a cycle is up to 28 days
Secondary Part 1: Time to Maximal Plasma Concentration (Tmax) of KB-0742 Cycle 1 Day 1 through Cycle 6 Day 1, where a cycle is up to 28 days
Secondary Part 2: Time to Maximal Plasma Concentration (Tmax) of KB-0742 Cycle 1 Day 1 and Cycle 1 Day 12, where a cycle is up to 28 days
Secondary Part 1: Area Under The Plasma Concentration x Time Curve From Hour 0 to The Last Measurable Time Point (AUC0-last) of KB-0742 Cycle 1 Day 1 through Cycle 6 Day 1, where a cycle is up to 28 days
Secondary Part 2: Trough Concentration (Ctrough) of KB-0742 Cycle 1 Day 1 and Cycle 1 Day 12, where a cycle is up to 28 days
Secondary Part 1 and Part 2: Progression Free Survival (PFS) Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 38 months)
Secondary Part 1 and Part 2: Disease Control Rate Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 38 months)
Secondary Part 1 and Part 2: Duration of Disease Control Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 38 months)
Secondary Part 1 and Part 2: Overall Response Rate (ORR) Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 38 months)
Secondary Part 1 and Part 2: Duration of Response (DOR) Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 38 months)
See also
  Status Clinical Trial Phase
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting NCT06018129 - A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT01939327 - Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma Phase 2
Completed NCT00503451 - A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01010295 - A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae Phase 2
Completed NCT00509379 - Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma Phase 2
Terminated NCT00383097 - Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma Phase 1
Completed NCT00992446 - Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Phase 2
Recruiting NCT05066958 - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT Phase 1/Phase 2
Active, not recruiting NCT05205512 - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial N/A
Recruiting NCT05006716 - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Completed NCT02767388 - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2